Wockhardt: Shares Rally 17% to 52-Week High on Strong Q4 and Drug Filing

🚀

stock soared 17% to hit a 52-week high of ₹1,809 on the NSE after filing for DCGI approval of its new drug, Zaynich, expected to launch in H2 FY25-26. Q4FY25 results showed ₹743 crore in revenue, 13% QoQ EBITDA growth, and reduced net losses. The company also reported fresh product launches and filings across multiple markets.